Development of a clinical formulation of 177Lu-PSMA for the treatment of prostate cancer

• Grant number: 17/15575-0
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: April 01, 2018
• End date: December 31, 2018
• Field of knowledge: Engineering - Nuclear Engineering - Applications of Radioisotopes
• Principal Investigator: Elba Cristina Sá de Camargo Etchebehere
• Grantee: Elba Cristina Sá de Camargo Etchebehere
• Company: Medicina Nuclear de Campinas Ltda
• CNAE: Atividades de serviços de complementação diagnóstica e terapêutica
• City: Campinas
• Pesquisadores principais: ALLAN DE OLIVEIRA SANTOS ; Celso Darío Ramos ; Emerson Soares Bernardes ; Mariana da Cunha Lopes de Lima ; Vânia Pereira de Castro Rodrigues

Abstract

The last decade has witnessed significant advances in the field of nuclear medicine therapy in Brazil with the approval of Lu-177 (for neuroendocrine tumors), Y-90 (for radioembolization) and recently Ra-223 (for bone metastases of prostate cancer). However, there is a great need for additional therapeutic options for patients with metastatic soft tissue prostate cancer. Based on the high and consistent expression of prostate specific membrane antigen (PSMA) in metastatic prostate cancer, the aim of this study is to develop a kit containing a PSMA inhibitor peptide for subsequent radiolabeling with 177Lu to be used as a therapy in patients with metastatic prostate cancer resistant to castration. Nowadays, patients with favorable financial conditions, seek this type of treatment (with radionuclides) abroad. SUS patients will have access to this type of treatment if they are eligible for some type of clinical trial. The rest of the population on the other hand will not have access to this treatment unless this product gets commercially available. Therefore we are seeking a national solution to a public health problem. (AU)